Emerging Stocks Down Under 26 July 2022: Tissue Repair (ASX:TRP)

Emerging Stocks Down Under 26 July 2022: Tissue Repair (ASX:TRP) 2
Tissue Repair: It all hinges on FDA approval
This week in Emerging Stocks Down Under, we look at another biotech, but this time it’s a newer company that arguably hasn’t had a chance to shine. Tissue Repair (ASX: TRP) listed in November last year at $1.15 per share and now sits at only 30 cents. Ouch! Arguably, it timed its IPO poorly, just as the equities boom of 2020-21 was fading. But it has some things that few biotechs have, let alone new listees – a completed Phase II program. So, has it been unfairly treated? Click here to read the previous edition of Emerging Stocks Down Under published 19 July 2022 For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter.
Please register or upgrade your plan to access this content.

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 5 publications per week
Weekly Investor Webinar
Profit Premium
$69
Get access to 5 publications per week
Access to the full research Archive
Weekly Investor Webinar
30-Day Free Trial
$0
No Credit Card Required!
Get access to 5 publications per week
Weekly Investor Webinar
Profit Premium
$59
BILLED ANNUALLY
Get access to 5 publications per week
Access to the full research Archive
Weekly Investor Webinar